BASILEA N | 32.300 / -0.92% |
Date/Time | 05/23 / 14:09 |
Chg. / Chg.(%) | -0.300 / -0.92% |
Bid | 32.200 / 353 |
Ask | 32.400 / 405 |
Open | 32.800 |
Previous Close | 32.600 |
High | 32.800 |
Low | 32.300 |
Volume [CHF] | 76,657.675 |
Volume [Units] | 2,356 |
Price fixings | 43 |
ISIN | CH0011432447 |
Security | BSLN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Bid Size | Bid | Ask | Ask size |
---|---|---|---|
353 | 32.200 | 32.400 | 405 |
259 | 32.150 | 32.450 | 32 |
73 | 32.100 | 32.500 | 125 |
67 | 32.050 | 32.550 | 67 |
472 | 32.000 | 32.600 | 166 |
192 | 31.950 | 32.650 | 76 |
1,950 | 31.900 | 32.700 | 368 |
150 | 31.850 | 32.750 | 220 |
550 | 31.800 | 32.800 | 550 |
409 | 31.750 | 32.850 | 2,656 |
News
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
03/08/2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
02/15/2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
01/24/2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
01/13/2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
01/11/2022 / 07:15 - GlobeNewswire